Resources from the same session
LBA66 - IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
Presenter: Axel Bex
Session: Proffered Paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA67 - Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
Presenter: Mohamad Allaf
Session: Proffered Paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA66 and LBA67
Presenter: Thomas Powles
Session: Proffered Paper session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1: GU tumours, non-prostate
Resources:
Webcast
1735O - PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)
Presenter: Enrique Grande Pulido
Session: Proffered Paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA74 - Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
Presenter: Thomas Powles
Session: Proffered Paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast